Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alzamend Neuro, Inc.

< Previous 1 2 Next >
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Pricing of Initial Public Offering
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro to Present at Sequire Biotechnology Conference
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.